RxDoctor Payments DataLook up a doctor →

Lawrence Ginsberg, MD

Psychiatry · Houston, TXNPI 1851385835

Payments from drug & device makers

$2,437,734in general payments, 2019–2025

Across 2,517 payments — averaging $968.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$549K
  • AbbVie$523K
  • F. Hoffmann-la Roche AG$220K
  • Supernus Pharmaceuticals, Inc.$189K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$145K
  • Boehringer Ingelheim$116K
  • plus $696K from 41 others
$383,587in research payments, 2019–2025

Across 58 payments — averaging $6613.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Otsuka Pharmaceutical Development & Commercialization, Inc.$198K
  • Purdue Pharma L.p.$176K
  • Jazz Pharmaceuticals Inc.$8K
  • Neos Therapeutics, LP$1K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Genentech, Inc.28$549,013
AbbVie(2 entities)393$522,868
F. Hoffmann-la Roche AG23$220,450
Supernus Pharmaceuticals, Inc.164$189,288
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)147$144,600
Boehringer Ingelheim6$115,548
Corium, LLC165$87,679
GW Research Limited7$78,301
Alkermes, Inc.204$57,334
Otsuka America Pharmaceutical, Inc.229$53,916
Jazz Pharmaceuticals Inc.54$50,065
E.r. Squibb & Sons, L.L.C.68$34,245
Hoffmann-la Roche Limited6$33,747
Ironshore Pharmaceuticals Inc.148$33,475
Teva Pharmaceuticals USA, Inc.125$32,404
Acadia Pharmaceuticals Inc11$30,758
Adlon Therapeutics L.p.11$30,551
Shire North American Group Inc19$30,195
Takeda Pharmaceuticals U.S.A., Inc.73$27,173
Idorsia Pharmaceuticals US Inc48$24,935
Neurocrine Biosciences, Inc.44$19,813
Boehringer Ingelheim International GmbH34$19,228
Eisai Inc.46$16,323
Tris Pharma Inc19$15,913
Otsuka Pharmaceutical Development & Commercialization, Inc.2$7,522
Boehringer Ingelheim Pharma GmbH & Co.kg7$5,105
Validus Pharmaceuticals LLC15$1,317
Lundbeck LLC86$1,087
Vanda Pharmaceuticals Inc.58$964
Almatica Pharma LLC59$764
Neos Therapeutics, LP77$732
Axsome Therapeutics, Inc.40$728
Johnson & Johnson26$454
Noven Therapeutics, LLC19$347
Bausch Health US, LLC15$184
Collegium Pharmaceutical, Inc.9$155
Livanova USA, Inc.7$146
Rhodes Pharmaceuticals L.p.4$72
Arbor Pharmaceuticals, Inc.4$59
OWP Pharmaceuticals, Inc.4$52
Sun Pharmaceutical Industries Inc.2$49
Aytu Biopharma, Inc.3$42
Biogen1$35
Avanir Pharmaceuticals, Inc.2$26
Novo Nordisk2$25
Vertical Pharmaceuticals, LLC2$24
Harmony Biosciences LLC1$19

How this compares

$2,437,734 in reported general payments places this provider in the 95th percentile of 2,238 psychiatry providers in Texas.

See all psychiatry providers in Texas

Medicare billing

Part B allowed, 2024
$56,078
Medicare patients
145
Services billed
590

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other psychiatry in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →